Filtered By:
Condition: Atrial Fibrillation
Management: WHO

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 22 results found since Jan 2013.

Anemia on admission predicts short‐ and long‐term outcomes in patients with acute ischemic stroke
ConclusionAnemia is common among AIS patients and is associated with cardiovascular comorbidities. Low hemoglobin status independently predicts short and long‐term mortality.
Source: International Journal of Stroke - November 27, 2014 Category: Neurology Authors: Haralampos Milionis, Vasileios Papavasileiou, Ashraf Eskandari, Suzette D'Ambrogio‐Remillard, George Ntaios, Patrik Michel Tags: Research Source Type: research

Incidence of Transient Ischemic Attack in Auckland, New Zealand, in 2011 to 2012 Clinical Sciences
Conclusions— This study describes the burden of TIA in an era of aggressive primary and secondary vascular risk factor management. Education programs for medical practitioners and patients around the identification and management of atrial fibrillation are required.
Source: Stroke - August 21, 2016 Category: Neurology Authors: Barber, P. A., Krishnamurthi, R., Parag, V., Anderson, N. E., Ranta, A., Kilfoyle, D., Wong, E., Green, G., Arroll, B., Bennett, D. A., Witt, E., Rush, E., Minsun Suh, F., Theadom, A., Rathnasabapathy, Y., Te Ao, B., Parmar, P., Feigin, V. L., for the ARC Tags: Epidemiology, Race and Ethnicity, Risk Factors, Cerebrovascular Disease/Stroke, Transient Ischemic Attack (TIA) Clinical Sciences Source Type: research

A Post-hoc Study of D-Amino Acid Oxidase in Blood as an Indicator of Post-stroke Dementia
In conclusion, our data support that plasma DAO levels were increased in PSD patients and correlated with brain WMH, independent of age, gender, hypertension, and renal function. Plasma DAO levels may therefore aid in PSD diagnosis. Introduction Stroke is a risk factor for both vascular dementia and Alzheimer's disease (1, 2). Functional recovery develops over the course of 26 weeks after a stroke (3), but the survivors are often left with disabilities. In addition to the sequelae of acute neuronal damage, the 1-year post-stroke dementia (PSD) rates after first-ever and recurrent stroke are ~10 and 30...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Platelet Count Predicts Adverse Clinical Outcomes After Ischemic Stroke or TIA: Subgroup Analysis of CNSR II
Conclusion: In ischemic stroke or TIA patients with platelet count within normal range, platelet count may be a qualified predictor for long-term recurrent stroke, mortality, and poor functional outcome. Introduction Platelets exert a critical role in the pathogenesis of atherosclerotic complications of cardio-cerebrovascular disease, contributing to thrombus formation, and embolism (1, 2). Previous literature reported that platelets of various size and density are produced by megakaryocytes of different size and stages of maturation in different clinical conditions, suggesting various platelet patterns in differen...
Source: Frontiers in Neurology - April 11, 2019 Category: Neurology Source Type: research

Stroke Prevention - Medical and Lifestyle Measures
Background: According to the World Health Organization, stroke is the ‘incoming epidemic of the 21st century'. In light of recent data suggesting that 85% of all strokes may be preventable, strategies for prevention are moving to the forefront in stroke management. Summary: This review discusses the risk factors and provides evidence on the effective medical interventions and lifestyle modifications for optimal stroke prevention. Key Messages: Stroke risk can be substantially reduced using the medical measures that have been proven in many randomized trials, in combination with effective lifestyle modifications. The glob...
Source: European Neurology - January 6, 2015 Category: Neurology Source Type: research

Epidemiology of young stroke in the ludhiana population-based stroke registry
Conclusion: Hypertension, diabetes mellitus, drug addiction, and tobacco intake were significantly associated with young stroke. Outcome was also better in younger people.
Source: Annals of Indian Academy of Neurology - February 22, 2022 Category: Neurology Authors: Monika Singla Gagandeep Singh Paramdeep Kaur Jeyaraj D Pandian Source Type: research

Antithrombotic treatment after stroke due to intracerebral haemorrhage
CONCLUSIONS: We did not identify beneficial or hazardous effects of short-term prophylactic dose parenteral anticoagulation and long-term oral antiplatelet therapy after ICH on important outcomes. Although there was a significant reduction in MACE and all major occlusive vascular events after long-term treatment with therapeutic dose oral anticoagulation for atrial fibrillation after ICH, the pooled estimates were imprecise, the certainty of evidence was only moderate, and effects on other important outcomes were uncertain. Large RCTs with a low risk of bias are required to resolve the ongoing dilemmas about antithrombotic...
Source: Cochrane Database of Systematic Reviews - January 26, 2023 Category: General Medicine Authors: Alexia Cochrane Chen Chen Jacqueline Stephen Ole Morten R ønning Craig S Anderson Graeme J Hankey Rustam Al-Shahi Salman Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Prevalence of Hypertension among Patients Attending Mobile Medical Clinics in the Philippines after Typhoon Haiyan
Conclusions Better planning and preparation by humanitarian actors seeking to decrease the overall morbidity and mortality associated with disasters should include treatment of NCDs. There is limited evidence regarding the optimal management of hypertension in disaster settings. Clinical care of patients with hypertension and other NCDs is an important part of disaster relief and recovery. We recommend future studies to determine best practices and evidence-based management of other NCDs (such as diabetes mellitus, cardiovascular disease, chronic lung disease, mental health etc.) in post-disaster settings. Competing Inter...
Source: PLOS Currents Disasters - December 20, 2016 Category: Global & Universal Authors: lindamob01 Source Type: research

Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk.
CONCLUSIONS: Our meta-analysis indicates that, in the short term, TAVI probably has little or no mortality difference compared to SAVR for severe AS in individuals with low surgical risk. Similarly, there is probably little or no difference in risk of stroke, MI, and cardiac death between the two approaches. TAVI may reduce the risk of rehospitalisation, but we are uncertain about the effects on LOS. TAVI reduces the risk of atrial fibrillation, AKI, and bleeding. However, this benefit is offset by the increased risk of PPM implantation. Long-term follow-up data are needed to further assess and validate these outcomes, esp...
Source: Cochrane Database of Systematic Reviews - December 19, 2019 Category: General Medicine Authors: Kolkailah AA, Doukky R, Pelletier MP, Volgman AS, Kaneko T, Nabhan AF Tags: Cochrane Database Syst Rev Source Type: research

The importance of extended working hours for work-related injuries
Discussion of Reduction Strategies and Behavioral Responses from a North American Perspective. Euro J Trans Infra Res. 2002;2(4). 21. POPM.gov [internet] Policy, Data, Oversight. Available from: https://www.opm.gov/policy-data-oversight/pay-leave/work-sched ules/fact-sheets/alternative-work-schedules-compressed-work-schedules/. Accessed June 30, 2021. 22. Kivimäki M, Nyberg ST, Batty GD, Fransson EI, Heikkilä K, Alfredsson L, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet. 2012;380(9852):1491-7. https://doi.org/10.1016/S0140-6736(12)60...
Source: Scandinavian Journal of Work, Environment and Health - August 11, 2021 Category: Occupational Health Tags: Editorial Source Type: research

Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.
CONCLUSIONS: There is evidence from RCTs to suggest that neither oral anticoagulation with warfarin or platelet inhibition with aspirin is better for mortality in systolic heart failure with sinus rhythm (high quality of the evidence for all-cause mortality and moderate quality of the evidence for non-fatal cardiovascular events and major bleeding events). Treatment with warfarin was associated with a 20% reduction in non-fatal cardiovascular events but a twofold higher risk of major bleeding complications (high quality of the evidence). We saw a similar pattern of results for the warfarin versus clopidogrel comparison (lo...
Source: Cochrane Database of Systematic Reviews - September 14, 2016 Category: Journals (General) Authors: Shantsila E, Lip GY Tags: Cochrane Database Syst Rev Source Type: research